- Home
- BNR vs UNCY Comparison
BNR vs UNCY Comparison
Compare BNR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- UNCY
- Stock Information
- Founded
- BNR 2014
- UNCY 2016
- Country
- BNR China
- UNCY United States
- Employees
- BNR N/A
- UNCY N/A
- Industry
- BNR Medical Specialities
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- UNCY Health Care
- Exchange
- BNR Nasdaq
- UNCY Nasdaq
- Market Cap
- BNR 38.3M
- UNCY 74.2M
- IPO Year
- BNR 2020
- UNCY 2021
- Fundamental
- Price
- BNR $12.20
- UNCY $4.58
- Analyst Decision
- BNR
- UNCY Strong Buy
- Analyst Count
- BNR 0
- UNCY 5
- Target Price
- BNR N/A
- UNCY $41.60
- AVG Volume (30 Days)
- BNR 35.1K
- UNCY 464.4K
- Earning Date
- BNR 12-02-2025
- UNCY 11-14-2025
- Dividend Yield
- BNR N/A
- UNCY N/A
- EPS Growth
- BNR N/A
- UNCY N/A
- EPS
- BNR N/A
- UNCY N/A
- Revenue
- BNR $74,862,782.00
- UNCY N/A
- Revenue This Year
- BNR $136.32
- UNCY N/A
- Revenue Next Year
- BNR N/A
- UNCY $19,392.60
- P/E Ratio
- BNR N/A
- UNCY N/A
- Revenue Growth
- BNR 5.20
- UNCY N/A
- 52 Week Low
- BNR $2.18
- UNCY $3.71
- 52 Week High
- BNR $13.89
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- BNR 60.62
- UNCY 48.04
- Support Level
- BNR $11.31
- UNCY $4.32
- Resistance Level
- BNR $13.89
- UNCY $5.39
- Average True Range (ATR)
- BNR 1.04
- UNCY 0.32
- MACD
- BNR 0.14
- UNCY -0.07
- Stochastic Oscillator
- BNR 71.31
- UNCY 24.29
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.